FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1968786896> ?p ?o ?g. }

• W1968786896 endingPage "2363" @default.
• W1968786896 startingPage "2363" @default.
• W1968786896 abstract "<h3>Context</h3>Atrial fibrillation (AF) is common, yet there remains an unmet medical need for additional treatment options. Current pharmacological treatments have limited efficacy and significant adverse events. Limited data from small trials suggest omega-3 polyunsaturated fatty acids may provide a safe, effective treatment option for AF patients.<h3>Objective</h3>To evaluate the safety and efficacy of prescription omega-3 fatty acids (prescription omega-3) for the prevention of recurrent symptomatic AF.<h3>Design, Setting, and Participants</h3>Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter trial involving 663 US outpatient participants with confirmed symptomatic paroxysmal (n = 542) or persistent (n = 121) AF, with no substantial structural heart disease, and in normal sinus rhythm at baseline were recruited from November 2006 to July 2009 (final follow-up was January 2010).<h3>Interventions</h3>Prescription omega-3 (8 g/d) or placebo for the first 7 days; prescription omega-3 (4 g/d) or placebo thereafter through week 24.<h3>Main Outcome Measures</h3>The primary end point was symptomatic recurrence of AF (first recurrence) in participants with paroxysmal AF. Secondary analyses included first recurrence in the persistent stratum and both strata combined. Participants were followed up for 6 months.<h3>Results</h3>At 24 weeks, in the paroxysmal AF stratum, 129 of 269 participants (48%) in the placebo group and 135 of 258 participants (52%) in the prescription group had a recurrent symptomatic AF or flutter event. In the persistent AF stratum, 18 participants (33%) in the placebo group and 32 (50%) in the prescription group had documented symptomatic AF or flutter events. There was no difference between treatment groups for recurrence of symptomatic AF in the paroxysmal stratum (hazard ratio [HR], 1.15; 95% confidence interval [CI], 0.90-1.46; P = .26), in the persistent stratum (HR, 1.64; 95% CI, 0.92-2.92; P = .09), and both strata combined (HR, 1.22; 95% CI, 0.98-1.52; P = .08). Other, secondary end points were supportive of the primary result. A total of 5% of those receiving placebo and 4% of those receiving prescription omega-3 discontinued due to adverse events. Eicosapentaenoic and docosahexaenoic acid blood levels were significantly higher in the prescription group than in the placebo group at weeks 4 and 24.<h3>Conclusion</h3>Among participants with paroxysmal AF, 24-week treatment with prescription omega-3 compared with placebo did not reduce recurrent AF over 6 months.<h3>Trial Registration</h3>clinicaltrials.gov Identifier: NCT00402363" @default.
• W1968786896 created "2016-06-24" @default.
• W1968786896 creator A5001241147 @default.
• W1968786896 creator A5020566430 @default.
• W1968786896 creator A5055404194 @default.
• W1968786896 creator A5066843009 @default.
• W1968786896 creator A5083179513 @default.
• W1968786896 date "2010-12-01" @default.
• W1968786896 modified "2023-10-10" @default.
• W1968786896 title "Efficacy and Safety of Prescription Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation" @default.
• W1968786896 cites W1496713467 @default.
• W1968786896 cites W1964656664 @default.
• W1968786896 cites W1973154574 @default.
• W1968786896 cites W1977159309 @default.
• W1968786896 cites W2001419766 @default.
• W1968786896 cites W2009299678 @default.
• W1968786896 cites W2015045003 @default.
• W1968786896 cites W2038468904 @default.
• W1968786896 cites W2045029453 @default.
• W1968786896 cites W2060315753 @default.
• W1968786896 cites W2062115516 @default.
• W1968786896 cites W2067748136 @default.
• W1968786896 cites W2091494523 @default.
• W1968786896 cites W2102591507 @default.
• W1968786896 cites W2106960442 @default.
• W1968786896 cites W2128788220 @default.
• W1968786896 cites W2164843796 @default.
• W1968786896 cites W2167075471 @default.
• W1968786896 cites W2172245650 @default.
• W1968786896 cites W2192223169 @default.
• W1968786896 cites W2598819486 @default.
• W1968786896 cites W3189113464 @default.
• W1968786896 cites W93028886 @default.
• W1968786896 doi "https://doi.org/10.1001/jama.2010.1735" @default.
• W1968786896 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21078810" @default.
• W1968786896 hasPublicationYear "2010" @default.
• W1968786896 type Work @default.
• W1968786896 sameAs 1968786896 @default.
• W1968786896 citedByCount "182" @default.
• W1968786896 countsByYear W19687868962012 @default.
• W1968786896 countsByYear W19687868962013 @default.
• W1968786896 countsByYear W19687868962014 @default.
• W1968786896 countsByYear W19687868962015 @default.
• W1968786896 countsByYear W19687868962016 @default.
• W1968786896 countsByYear W19687868962017 @default.
• W1968786896 countsByYear W19687868962018 @default.
• W1968786896 countsByYear W19687868962019 @default.
• W1968786896 countsByYear W19687868962020 @default.
• W1968786896 countsByYear W19687868962021 @default.
• W1968786896 countsByYear W19687868962022 @default.
• W1968786896 countsByYear W19687868962023 @default.
• W1968786896 crossrefType "journal-article" @default.
• W1968786896 hasAuthorship W1968786896A5001241147 @default.
• W1968786896 hasAuthorship W1968786896A5020566430 @default.
• W1968786896 hasAuthorship W1968786896A5055404194 @default.
• W1968786896 hasAuthorship W1968786896A5066843009 @default.
• W1968786896 hasAuthorship W1968786896A5083179513 @default.
• W1968786896 hasBestOaLocation W19687868961 @default.
• W1968786896 hasConcept C126322002 @default.
• W1968786896 hasConcept C142724271 @default.
• W1968786896 hasConcept C151730666 @default.
• W1968786896 hasConcept C164705383 @default.
• W1968786896 hasConcept C168563851 @default.
• W1968786896 hasConcept C187212893 @default.
• W1968786896 hasConcept C197934379 @default.
• W1968786896 hasConcept C202061045 @default.
• W1968786896 hasConcept C203092338 @default.
• W1968786896 hasConcept C204787440 @default.
• W1968786896 hasConcept C2426938 @default.
• W1968786896 hasConcept C27081682 @default.
• W1968786896 hasConcept C2779161974 @default.
• W1968786896 hasConcept C2779343474 @default.
• W1968786896 hasConcept C2991744798 @default.
• W1968786896 hasConcept C71924100 @default.
• W1968786896 hasConcept C86803240 @default.
• W1968786896 hasConcept C98274493 @default.
• W1968786896 hasConceptScore W1968786896C126322002 @default.
• W1968786896 hasConceptScore W1968786896C142724271 @default.
• W1968786896 hasConceptScore W1968786896C151730666 @default.
• W1968786896 hasConceptScore W1968786896C164705383 @default.
• W1968786896 hasConceptScore W1968786896C168563851 @default.
• W1968786896 hasConceptScore W1968786896C187212893 @default.
• W1968786896 hasConceptScore W1968786896C197934379 @default.
• W1968786896 hasConceptScore W1968786896C202061045 @default.
• W1968786896 hasConceptScore W1968786896C203092338 @default.
• W1968786896 hasConceptScore W1968786896C204787440 @default.
• W1968786896 hasConceptScore W1968786896C2426938 @default.
• W1968786896 hasConceptScore W1968786896C27081682 @default.
• W1968786896 hasConceptScore W1968786896C2779161974 @default.
• W1968786896 hasConceptScore W1968786896C2779343474 @default.
• W1968786896 hasConceptScore W1968786896C2991744798 @default.
• W1968786896 hasConceptScore W1968786896C71924100 @default.
• W1968786896 hasConceptScore W1968786896C86803240 @default.
• W1968786896 hasConceptScore W1968786896C98274493 @default.
• W1968786896 hasIssue "21" @default.
• W1968786896 hasLocation W19687868961 @default.
• W1968786896 hasLocation W19687868962 @default.
• W1968786896 hasOpenAccess W1968786896 @default.

• next